drugset / Trial / NCT04944511
PD-1 Antibody Improve Mixed Chimerism
NaSingle-groupOpen-labelTreatment
Summary
PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape. We intend to use PD-1 antibody to improve the function of lymhocyte and improve the chimerism in patients after allo-HCT.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2023-01
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
Indications
No indication recorded.